New hope for rare muscle diseases: drug shows promise in long-term trial

NCT ID NCT04628936

First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 21 times

Summary

This study looked at the long-term safety and effectiveness of a drug called KZR-616 in 18 adults with active polymyositis or dermatomyositis, rare diseases that cause muscle inflammation and weakness. Participants had already completed a previous study and continued taking KZR-616 for up to 48 weeks. The goal was to see if the drug could improve muscle strength and function over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • KZR Research Site

    Beverly Hills, California, 90211, United States

  • KZR Research Site

    Orange, California, 92868, United States

  • KZR Research Site

    Miami, Florida, 33136, United States

  • KZR Research Site

    Kansas City, Kansas, 66160, United States

  • KZR Research Site

    Baltimore, Maryland, 21224, United States

  • KZR Research Site

    Ann Arbor, Michigan, 48109, United States

  • KZR Research Site

    Duncansville, Pennsylvania, 16635, United States

  • KZR Research Site

    Pittsburgh, Pennsylvania, 15213, United States

  • KZR Research Site

    Austin, Texas, 78756, United States

  • KZR Research Site

    Prague, Czechia

Conditions

Explore the condition pages connected to this study.